Teva Pharmaceutical (NYSE:TEVA) lost ~13%, posting what could be its biggest intraday decline since March 2020 after the generic drugmaker set its 2025 earnings outlook below consensus even as its Q4 ...
Hosted on MSN8h
Teva Stock Dives 14%. Why Its CEO Says It's A Victim.Teva Pharmaceutical is a victim of its own success, Chief Executive Richard Francis said Wednesday as Teva stock plummeted on ...
The US FDA has warned Sanofi about significant deviations from Current Good Manufacturing Practice for active pharmaceutical ingredients.
Dupixent continues leading among Sanofi’s portfolio, and it’s poised for up to $20 billion in peak sales. Read my SNY ...
BUSINESS OPERATING PROFIT FORECAST: Business operating profit--one of the company's preferred metrics, which strips out exceptional items--is forecast at 2.08 billion euros, according to the Vara ...
Atalanta Therapeutics has bagged $97 million, money the biotech plans to use to launch clinical trials for its small ...
Sanofi's SNY +1.27% + Free Alerts short percent of float has risen 11.76% since its last report. The company recently ...
J.P. Morgan analyst Richard Vosser maintained a Hold rating on Sanofi (SNYNF – Research Report) today and set a price target of €105.00. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback